<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04528394</url>
  </required_header>
  <id_info>
    <org_study_id>SPHIC-TR-HNCNS-2019-32</org_study_id>
    <nct_id>NCT04528394</nct_id>
  </id_info>
  <brief_title>Proton Versus Photon Radiotherapy for Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Randomized Phase II Trial Evaluating Toxicity and Efficacy Between Proton and Photon for Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Proton and Heavy Ion Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Proton and Heavy Ion Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the toxicity and therapeutic efficacy of proton or&#xD;
      photon combined with carbon ion radiotherapy for newly diagnosed nasopharyngeal&#xD;
      carcinoma.Participants will be randomized to 2 arms. Arm 1, participants received photon&#xD;
      combined with carbon ion radiotherapy group, Arm 2, participants received proton combined&#xD;
      with carbon ion radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the toxicity and therapeutic efficacy of photon or&#xD;
      proton combined with carbon ion radiotherapy for newly diagnosed nasopharyngeal&#xD;
      carcinoma.Participants will be randomized to 2 arms. Arm 1 participants received photon&#xD;
      combined with carbon ion radiotherapy (photon: 56 Gy/28 Fx, plus carbon: 15-17.5 gray&#xD;
      equivalent [GyE]/5 Fx for boost). Arm 2, participants received proton combined with carbon&#xD;
      ion radiotherapy (proton: 56 GyE/28 Fx, plus carbon: 15-17.5 GyE/5 Fx for boost). Adverse&#xD;
      events will be documented according to CTCAE v4.03.The response of treatment will be&#xD;
      evaluated according to RECIST criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related Xerostomia (≥Grade 2) as assessed by NCI CTCAE v4.03</measure>
    <time_frame>Xerostomia (≥Grade 2) occurred at 6 months after completion of radiotherapy</time_frame>
    <description>CTCAE refers to Common Terminology Criteria for Adverse Events, which is one of the most frequently used criteria for toxicity grading after anti-cancer treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival of all patients</measure>
    <time_frame>From randomization to death, a median of 3 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival of all patients</measure>
    <time_frame>From randomization to death or disease progression, a median of 3 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control</measure>
    <time_frame>From randomization to local failure, a median of 3 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional control</measure>
    <time_frame>From randomization to regional failure, a median of 3 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant control</measure>
    <time_frame>From randomization to distant failure, a median of 3 year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events as assessed by NCI CTCAE v4.03</measure>
    <time_frame>Time interval from start to 3 months after completion of radiotherapy.</time_frame>
    <description>Acute and late toxicities induced by radiation therapy other than xerostomia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Photon combined with Carbon ion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants received photon: 56 Gy/28 Fx for high-risk area(CTVhigh), 50.4 Gy/28 Fx for lower neck low-risk area(CTVlow), plus carbon ion: 15-17.5 GyE/5 Fx for boost for visible tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proton combined with Carbon ion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants received proton: 56 GyE/28 Fx for high-risk area(CTVhigh), 50.4 GyE/28 Fx for lower neck low-risk area(CTVlow), plus carbon ion: 15-17.5 GyE/5 Fx for boost for visible tumors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Photon</intervention_name>
    <description>Photon combined with Carbon ion in Arm 1</description>
    <arm_group_label>Photon combined with Carbon ion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton</intervention_name>
    <description>Proton combined with Carbon ion in Arm 2</description>
    <arm_group_label>Proton combined with Carbon ion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Carbon ion</intervention_name>
    <description>Same dose and fractionation will be used in both arms.</description>
    <arm_group_label>Photon combined with Carbon ion</arm_group_label>
    <arm_group_label>Proton combined with Carbon ion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed Nasopharyngeal carcinoma(WHO II/III type).&#xD;
&#xD;
          -  Age ≥ 18 and ≤ 70 years of age.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group score: 0-1.&#xD;
&#xD;
          -  Adequate laboratory values within 30 dyas of enrollment to study defined as follows:&#xD;
             1) neutrophil &gt; 2000/mm^3; 2) platelet &gt; 100,000/mm^3; 3) total bilirubin &lt; 1.5mg/dl;&#xD;
             4) alanine aminotransferase/aspartate aminotransferase &lt; 1.5 upper limit of normal; 5)&#xD;
             SCr &lt; 1.5mg/dl; creatinine clearance rate &gt; 60ml/min.&#xD;
&#xD;
          -  Willing to accept adequate contraception for women with childbearing potential.&#xD;
&#xD;
          -  Willing to sign the written informed consent; Informed consent must be signed before&#xD;
             the enrollment in the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of distant metastasis.&#xD;
&#xD;
          -  Received radiotherapy for head and neck before.&#xD;
&#xD;
          -  Received surgery(except for biopsy) for primary lesion or cervical lymph node.&#xD;
&#xD;
          -  Previous history of malignant tumor (within 5 years) or simultaneous existence of&#xD;
             multiple primary tumors.&#xD;
&#xD;
          -  Presence of diseases (such as Sjögren syndrome) that may interfere evaluation of&#xD;
             xerostomia.&#xD;
&#xD;
          -  Accompanied with severe major organ dysfunction.&#xD;
&#xD;
          -  Presence of mental disease that may influence the understanding of informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiade Lu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Proton and Heavy Ion Center,Shanghai, SPHIC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Kong, MD</last_name>
    <phone>133XXX</phone>
    <email>lin.kong@sphic.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiyi Hu, MD</last_name>
    <phone>1333XXX</phone>
    <email>jiyi.hu@sphic.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Proton and Heavy Ion Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201315</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Kong, MD</last_name>
      <email>lin.kong@sphic.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jiyi Hu, MD</last_name>
      <email>jiyi.hu@sphic.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Jiade J Lu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Proton and Heavy Ion Center</investigator_affiliation>
    <investigator_full_name>Jiade J. Lu</investigator_full_name>
    <investigator_title>Executive Vice-President</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal carcinoma</keyword>
  <keyword>Intensity-modulated radiation therapy</keyword>
  <keyword>Proton beam therapy</keyword>
  <keyword>Carbon-ion radiotherapy</keyword>
  <keyword>Toxicity</keyword>
  <keyword>Survival</keyword>
  <keyword>Disease control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data including baseline characteristics, treatment information and follow-up data on toxicity, survival and disease control will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Within 5 years after the publication of the study</ipd_time_frame>
    <ipd_access_criteria>Data may be shared with radiation oncologists who are interested in examining the efficacy and toxicity of nasopharyngeal carcinoma patients treated with particle beam radiotherapy. Pooled analysis comparing IMRT and particle beam radiotherapy will be of particular interest. Detailed study protocol should be emailed along with the request of the data. We may carefully review the study protocol, and data will only be shared with well-designed studies.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

